<DOC>
	<DOCNO>NCT00929110</DOCNO>
	<brief_summary>This study design investigate 1 year efficacy safety 50 µg daily ( od ) dose glycopyrronium bromide ( NVA237 ) patient moderate severe chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>1-year Study Assess Efficacy , Safety , Tolerability Glycopyrronium Bromide ( NVA237 ) Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Male female adult age ≥ 40 year , sign Informed Consent Form prior initiation studyrelated procedure . 2 . Patients moderate severe stable chronic obstructive pulmonary disease ( COPD , Stage II Stage III ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines 2008 . 3 . Current exsmokers smoke history least 10 pack year . 4 . Patients postbronchodilator force expiratory volume 1 second ( FEV1 ) ≥ 30 % &lt; 80 % predict normal , postbronchodilator FEV1/forced vital capacity ( FVC ) &lt; 0.7 Visit 2 ( Day 14 ) . 5 . Patients , accord daily electronic diary data Visit 2 ( Day 14 ) Visit 3 ( Day 1 ) , total score 1 least 4 last 7 day prior Visit 3 ( Day 1 ) . 1 . Pregnant woman nurse mother ( pregnancy confirm positive urine pregnancy test ) . 2 . Women childbearing potential , unless use approve method medical surgical contraception . 3 . Patients require long term oxygen therapy ( &gt; 15 h day ) daily basis chronic hypoxemia , hospitalize exacerbation airways disease 6 week prior Visit 1 ( Day 21 ) Visit 1 ( Day 21 ) Visit 3 ( Day 1 ) . 4 . Patients respiratory tract infection within 6 week prior Visit 1 ( Day 21 ) . 5 . Patients , judgment investigator responsible Novartis personnel , clinically relevant laboratory abnormality clinically significant condition . 6 . Patients history asthma indicate ( limited ) blood eosinophil count &gt; 600/mm^3 ( Visit 1 , Day 21 ) onset symptom prior age 40 year . 7 . Patients history long QT syndrome whose QTc measure Visit 1 ( Day 21 ) ( Fridericia method ) prolong ( &gt; 450 m male &gt; 470 m female . Other protocoldefined inclusion/exclusion criterion may apply study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>NVA237</keyword>
	<keyword>glycopyrronium bromide</keyword>
</DOC>